“RMAT designation is another important regulatory milestone for CTX001 and underscores the transformative potential of a CRISPR-based therapy for patients with severe hemoglobinopathies,” said Samarth Kulkarni, Ph.D., Chief
The company has secured approval from the Drugs Controller General of India (DCGI) to begin the trial with Favipiravir at the end of April. Favipiravir is a generic
Retevmo was approved under the FDA’s Accelerated Approval regulations based on the LIBRETTO-001 Phase 1/2 trial’s endpoints of objective response rate (ORR) and duration of response (DoR). Continued
Enhertu, a HER2-directed antibody drug conjugate (ADC), is being studied under a comprehensive development programme to assess the efficacy and safety of the monotherapy across multiple HER2-driven cancers
Certara will support the DMTC-led clinical trial by analyzing study data to develop mathematical models to understand the viral time course and factors impacting drug exposure and prophylactic
The partnership will focus on the testing of a plant produced antigens in a vaccine for Covid-19, the disease resulted due to the SARS-CoV-2 novel coronavirus VIDO-InterVac director
Twist has also found antibody candidates that bind with high affinity to the human ACE2 cellular receptor, the binding site of SARS-CoV-2 in the human body. The rapid
The approval has been granted for Tabrecta, a MET inhibitor, to treat adult patients with NSCLC whose tumours have a mutation, which leads to METex14 as detected by
In response to the COVID-19 pandemic, CIRM recently approved emergency funding and the allocation of $5 million for peer-reviewed regenerative medicine and stem cell research that could quickly
Based in South San Francisco of California, Portola is engaged in the discovery, development and commercialisation of novel therapeutics for thrombosis and other haematologic conditions. The company’s commercialised
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.